The report "Clinical Chemistry Analyzers Market by Product [Analyzers (Fully Automated, PoC, Semi-automated), Reagents], Test Type [Lipid Profile, Liver, Basic Metabolic Panels], End User [Hospitals & Clinics, Research, Labs], Region - Global Forecast to 2030" The clinical chemistry analyzers market is valued at an estimated USD 25.92 billion in 2025 and is projected to reach USD 20.86 billion by 2030 at a CAGR of 5.6% during the forecast period.
Browse 270 market data Tables and 50 Figures spread through 235 Pages and in-depth TOC on "Clinical Chemistry Analyzers Market by Product [Analyzers (Fully Automated, PoC, Semi-automated), Reagents], Test Type [Lipid Profile, Liver, Basic Metabolic Panels], End User [Hospitals & Clinics, Research, Labs], Region - Global Forecast to 2030."
Download PDF - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=144027310
The clinical chemistry analyzers market is witnessing steady growth, driven mainly by the rising prevalence of chronic and lifestyle-related diseases and an increasing elderly population. The growing adoption of point-of-care testing is further supporting market expansion, as these devices enable faster, more accessible, and convenient diagnostic solutions. Additionally, the ongoing modernization of healthcare infrastructure and the rising demand for efficient laboratory automation are creating new opportunities for market players, fostering innovation and improving overall diagnostic capabilities.
The hospitals & clinics segment accounted for the largest share of the clinical chemistry analyzers market, by end user segment, in 2024
By end users, the clinical chemistry analyzers market is segmented into hospitals & clinics, diagnostic laboratories, research laboratories and institutes, and other end users. In 2024, hospitals & clinics accounted for the largest share of the market. This segment’s growth is primarily driven by the increasing incidence of various diseases and disorders, the rising adoption of clinical chemistry analyzers in healthcare facilities, and ongoing technological advancements that enhance diagnostic efficiency and accuracy.
Inquiry Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=144027310
The lipid profile tests segment is expected to register the highest growth rate during the forecast period.
The clinical chemistry analyzers market, segmented by test type, comprises basic metabolic panels, liver function panels, lipid profiles, renal function panels, thyroid function panels, electrolyte panels, and specialty chemical tests. The lipid profiles segment recorded the highest growth rate, mainly due to the increasing incidence of obesity and associated health complications such as cardiovascular diseases and metabolic disorders. Growing awareness of preventive healthcare and the importance of regular lipid monitoring has further contributed to the rising demand for lipid profile testing in clinical settings.
North America is the largest regional market for clinical chemistry analyzers.
The clinical chemistry analyzers market is segmented into five regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2024, North America accounted for the largest market share. This leading position is driven by factors such as a growing geriatric population, the rising prevalence of chronic and lifestyle-related diseases, supportive government initiatives, increased healthcare spending, well-developed healthcare infrastructure, and the availability of advanced diagnostic instruments.
The major players operating in this market are Abbott Laboratories (US), F. Hoffmann-La Roche Ltd. (Switzerland), Siemens Healthineers AG (Germany), Danaher Corporation (US), Thermo Fisher Scientific Inc. (US), HORIBA Ltd. (Japan), Sysmex Corporation (Japan), Hitachi, Ltd. (Japan), EKF Diagnostics Holdings plc (UK), and QuidelOrtho Corporation (US).
